You are here: Industry Insights > Rubraca

News List

Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer pharmaceutical-business-review
June 17, 2020
Clovis Oncology announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP) ...
FDA grants Clovis’ Rubraca fast track designation for prostate cancer pharmaceutical-technology
January 17, 2020
Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration (FDA) for Rubraca (rucaparib) as a monotherapy for BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer (mCRPC) adult patients.
CHMP Grants Positive Opinion for New Indication of Rubraca americanpharmaceuticalreview
December 17, 2018
Clovis Oncology announced the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending.....
Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting pharmatimes
July 10, 2018
European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
New US approval for Clovis' Rubraca pharmatimes
April 10, 2018
Clovis' PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.